Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record

Paradigm Biopharmaceuticals ("Paradigm"), a global biopharmaceutical company specializing in repurposing existing drugs for unmet medical needs, announced their retention of Rubenstein Public Relations (RPR) as its agency of record.

RPR will provide counsel to Paradigm on their corporate messaging and guide the development of their brand positioning in both the U.S. and global markets.

"We are excited to begin our partnership with RPR, as their firm is well-equipped to guide our company across the U.S. media landscape and highlight our innovative therapies which have the potential to enhance the quality of life of millions," said Paradigm CMO and Interim CEO, Dr. Donna Skerrett.